Aibotics Therapies, Inc. (AIBT)
AIBT is quoted over the counter, not listed on an exchange. Aibotics Therapies, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | AIBT, quoted over the counter |
| SEC CIK | 0001763329 |
| OTC Markets tier | OTCID (price source, 2026-11-13) |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Business address | Heyburn, ID |
| Incorporated in | NV |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year after that date that the consolidated financial statements are issued." | 10-Q 2026-08-19 |
| Cash and burn | $233K cash; operating cash flow -$87K a quarter. | Report 2026-06-30 |
| Shares outstanding | 850,165,334 (2026-08-19); 191,904,437 a year earlier; 14,896,791 three years earlier. | Cover page 2026-08-19 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Fruci & Associates II, PLLC, Spokane, Washington, United States | PCAOB Form AP 2026-04-22 |
| Late filings, 12 months | 3 NT notices | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$537K | -$47K | $233K | $2.4M | $0 | 10-Q 2026-08-19 |
| Q1 2026 2026-03-31 | $0 | -$418K | -$36K | $289K | $2.6M | $0 | 10-Q 2026-06-09 |
| Q4 2025 2025-12-31 | $0 | -$608K | -$87K | $256K | $2.4M | $2K | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | $0 | -$530K | -$179K | $230K | $2.8M | $2K | 10-Q 2025-11-19 |
| Q2 2025 2025-06-30 | $0 | -$486K | -$165K | $242K | $2.9M | $2K | 10-Q 2026-08-19 |
| Q1 2025 2025-03-31 | $2K | -$591K | -$28K | $157K | $2.4M | $2K | 10-Q 2026-06-09 |
| Q4 2024 2024-12-31 | $0 | -$492K | -$17K | $185K | $2.4M | $0 | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | $0 | -$460K | -$78K | $202K | $2.4M | Needs four quarters | 10-Q 2025-11-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 253G2 | 2025-07-03 |
| Latest annual report | 10-K | 2026-04-15 |
| Latest quarterly / interim | 10-Q | 2026-08-19 |
| Latest current report | 8-K | 2026-10-16 |
Source: SEC EDGAR submissions feed, 111 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier